Establishment of a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish

Journal of Toxicological Sciences

Volumn 39, Issue 4, 2014, Pages 579-600

  Koseki, Naoteru ^a   Deguchi, Jiro ^a   Yamashita, Akihito ^a   Miyawaki, Izuru ^a   Funabashi, Hitoshi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Extending exposure time; Flashlight stimulation; Locomotor activity; Seizure; Zebrafish

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; AMOXAPINE; CAMPHOR; CIPROFLOXACIN; CISPLATIN; CYCLOSPORIN; DIMETHYL SULFOXIDE; DISOPYRAMIDE; ENOXACIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; FOLIC ACID; ISONIAZID; LIDOCAINE; MEFENAMIC ACID; NIFEDIPINE; OFLOXACIN; PAROXETINE; PENICILLIN G; PENTETRAZOLE; PICROTOXIN; PROPAFENONE; PROPRANOLOL; ROPINIROLE; SERTRALINE; SPARFLOXACIN; TRAZODONE; UNINDEXED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SCREENING; LARVA; LOCOMOTION; METHODOLOGY; NONHUMAN; PHOTOSTIMULATION; PREDICTIVE VALUE; SEIZURE; VALIDATION STUDY; VELOCITY; ZEBRA FISH; ADVERSE DRUG REACTION; ANIMAL; CHEMICALLY INDUCED; DRUG DEVELOPMENT; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; MOTOR ACTIVITY; PHYSIOLOGY; PROCEDURES; TOXICOLOGY;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; MOTOR ACTIVITY; PHOTIC STIMULATION; SEIZURES; TOXICOLOGY; ZEBRAFISH;

EID: 84904972854     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.39.579     Document Type: Article

References (110)

1. Ali, S., Champagne, D.L. and Richardson, M.K. (2012): Behavioral profiling of zebrafish embryos exposed to a panel of 60 watersoluble compounds. Behav. Brain Res., 228, 272-283.
2. Amabeoku, G.J. and Syce, J.A. (1997): Propranolol-induced seizures in mice: the role of noradrenaline. Cell Mol. Life Sci., 53, 646-651.
3. Anabuki, K., Kitajima, S. and Koda, S. (1982a): The general pharmacological test of cisplatin. Jpn. Pharmacol. Ther., 10, 733-754. (in Japanese)
4. Anabuki, K., Koda, S. and Takahashi, N. (1982b): Acute toxicity study of cisplatin in mice and rats. Jpn. Pharmacol. Ther., 10, 723-731. (in Japanese)
5. Atkinson, W.L., Arden, N.H., Patriarca, P.A., Leslie, N., Lui, K.J. and Gohd, R. (1986): Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch. Intern. Med., 146, 1751-1756.
6. Baǧirici, F. and Bostanci, M.O. (2006): Anticonvulsive effects of nimodipine on penicillin-induced epileptiform activity. Acta Neurobiol. Exp. (Wars), 66, 123-128.
7. Banote, R.K., Koutarapu, S., Chennubhotla, K.S., Chatti, K. and Kulkarni, P. (2013): Oral gabapentin suppresses pentylenetetrazole-induced seizure-like behavior and cephalic field potential in adult zebrafish. Epilepsy Behav., 27, 212-219.
8. Baraban, S.C., Taylor, M.R., Castro, P.A. and Baier, H. (2005): Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience, 131, 759-768.
9. Barrons, R.W., Murray, K.M. and Richey, R.M. (1992): Populations at risk for penicillin-induced seizures. Ann. Pharmacother., 26, 26-29.
10. Blas-Valdivia, V., Cano-Europa, E., Hernandez-Garcia, A. and Ortiz-Butron, R. (2007): Hippocampus and amygdala neurotoxicity produced by systemic lidocaine in adult rats. Life Sci., 81, 691-694.
11. Burgess, H.A. and Granato, M. (2007): Modulation of locomotor activity in larval zebrafish during light adaptation. J. Exp. Biol., 210, 2526-2539.
12. Capovilla, G., Beccaria, F., Gambardella, A., Montagnini, A., Avantaggiato, P. and Seri, S. (2007): Photosensitive benign myoclonic epilepsy in infancy. Epilepsia, 48, 96-100.
13. Chen, J., Patel, R., Friedman, T.C. and Jones, K.S. (2010): The behavioral and pharmacological actions of NMDA receptor antagonism are conserved in zebrafish larvae. Int. J. Comp. Psychol., 23, 82-90.
14. Chen, Y.W., Shieh, J.P., Chen, Y.C., Leung, Y.M., Hung, C.H. and Wang, J.J. (2012): Cutaneous analgesia after subcutaneous injection of memantine and amantadine and their systemic toxicity in rats. Eur. J. Pharmacol., 693, 25-30.
15. Cheng, C.Y., Lin, Y.C., Chen, J.S., Chen, C.H. and Deng, S.T. (2011): Cisplatin-induced acute hyponatremia leading to a seizure and coma: a case report. Chang Gung Med. J., 34, 48-51.
16. Cherng, C.H. and Wong, C.S. (2005): Effect of fentanyl on lidocaine-induced convulsions in mice. Pharmacology, 75, 1-4.
17. Chow, K.M., Hui, A.C. and Szeto, C.C. (2005): Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur. J. Clin. Microbiol. Infect. Dis., 24, 649-653.
18. Christ, W. (1990): Central nervous system toxicity of quinolones: human and animal findings. J. Antimicrob. Chemother., 26, 219-225.
19. Churchill, J.A. and Gammon, G.D. (1949): The effect of antihistaminic drugs on convulsive seizures. J. Am. Med. Assoc., 141, 18-21.
20. Coyer, J.R. and Nicholson, D.P. (1976): Isoniazid-induced convulsions. South Med. J., 69, 294-297.
21. Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D. and Quack, G. (1994): Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine. J. Neural Transm. Park. Dis. Dement. Sect., 7, 155-166.
22. Deshpande, L.S., Lou, J.K., Mian, A., Blair, R.E., Sombati, S. and DeLorenzo, R.J. (2007): In vitro status epilepticus but not spontaneous recurrent seizures cause cell death in cultured hippocampal neurons. Epilepsy Res., 75, 171-179.
23. DeToledo, J.C. (2000): Lidocaine and seizures. Ther. Drug Monit., 22, 320-322.
24. Easter, A., Sharp, T.H., Valentin, J.P. and Pollard, C.E. (2007): Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability. J. Pharmacol. Toxicol. Methods, 56, 223-233.
25. Fujihara, A., Miyata, K., Ozawa, Y., Tomioka, K. and Ida, H. (1987): General pharmacology of propafenone hydrochloride. The Clinical Report, 21, 2639-2655. (in Japanese)
26. Fujii, Y., Tanaka, T., Harada, C., Hirai, T. and Kamei, C. (2003): Epileptogenic activity induced by histamine H(1) antagonists in amygdala-kindled rats. Brain Res., 991, 258-261.
27. Furshpan, E.J. (1989): A cell-culture approach to the study of seizure activity. Q. J. Exp. Physiol., 74, 975-985.
28. Goldsmith, P. and Fleming, A.L. (2005): Screening methods employing zebrafish and the blood brain barrier. International patent, WO/2005/080974.
29. Goldstone, J.V., McArthur, A.G., Kubota, A., Zanette, J., Parente, T., Jonsson, M.E., Nelson, D.R. and Stegeman, J.J. (2010): Identification and developmental expression of the full complement of Cytochrome P450 genes in zebrafish. BMC Genomics, 11, 643.
30. Guler, G., Erdogan, F., Golgeli, A., Akin, A. and Boyaci, A. (2005): Ketamine reduces lidocaine-induced seizures in mice. Int. J. Neurosci., 115, 1239-1244.
31. Harmant, J., van Rijckevorsel-Harmant, K., de Barsy, T. and Hendrickx, B. (1990): Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet, 336, 386.
32. Harrison, P.K., Sheridan, R.D., Green, A.C., Scott, I.R. and Tattersall, J.E. (2004): A guinea pig hippocampal slice model of organophosphate-induced seizure activity. J. Pharmacol. Exp. Ther., 310, 678-686.
33. Higashijima, S., Mandel, G. and Fetcho, J.R. (2004): Distribution of prospective glutamatergic, glycinergic, and GABAergic neurons in embryonic and larval zebrafish. J. Comp. Neurol., 480, 1-18.
34. Hori, S., Kizu, J. and Kawamura, M. (2003): Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J. Infect. Chemother., 9, 314-320.
35. Hori, S. and Shimada, J. (1993): Effects of quinolones on the central nervous system. In Quinolone antimicrobial agents 2nd ed (Hooper, D.C. and Wolfson, J.S. ed.), pp.513-518, American society for microbiology, Washington DC.
36. Hori, S., Shimada, J., Shiba, K., Yoshida, M., Saito, A. and Sakai, O. (1991): A study on convulsive effects of spafloxacin with or without non-steroidal anti-inflammatory drugs. Chemotherapy, 39, 161-166. (in Japanese)
37. Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., Humphray, S., McLaren, K., Matthews, L., McLaren, S., Sealy, I., Caccamo, M., Churcher, C., Scott, C., Barrett, J.C., Koch, R., Rauch, G.J., White, S., Chow, W., Kilian, B., Quintais, L.T., Guerra-Assuncao, J.A., Zhou, Y., Gu, Y., Yen, J., Vogel, J.H., Eyre, T., Redmond, S., Banerjee, R., Chi, J., Fu, B., Langley, E., Maguire, S.F., Laird, G.K., Lloyd, D., Kenyon, E., Donaldson, S., Sehra, H., Almeida-King, J., Loveland, J., Trevanion, S., Jones, M., Quail, M., Willey, D., Hunt, A., Burton, J., Sims, S., McLay, K., Plumb, B., Davis, J., Clee, C., Oliver, K., Clark, R., Riddle, C., Eliott, D., Threadgold, G., Harden, G., Ware, D., Mortimer, B., Kerry, G., Heath, P., Phillimore, B., Tracey, A., Corby, N., Dunn, M., Johnson, C., Wood, J., Clark, S., Pelan, S., Griffiths, G., Smith, M., Glithero, R., Howden, P., Barker, N., Stevens, C., Harley, J., Holt, K., Panagiotidis, G., Lovell, J., Beasley, H., Henderson, C., Gordon, D., Auger, K., Wright, D., Collins, J., Raisen, C., Dyer, L., Leung, K., Robertson, L., Ambridge, K., Leongamornlert, D., McGuire, S., Gilderthorp, R., Griffiths, C., Manthravadi, D., Nichol, S., Barker, G., Whitehead, S., Kay, M., Brown, J., Murnane, C., Gray, E., Humphries, M., Sycamore, N., Barker, D., Saunders, D., Wallis, J., Babbage, A., Hammond, S., Mashreghi-Mohammadi, M., Barr, L., Martin, S., Wray, P., Ellington, A., Matthews, N., Ellwood, M., Woodmansey, R., Clark, G., Cooper, J., Tromans, A., Grafham, D., Skuce, C., Pandian, R., Andrews, R., Harrison, E., Kimberley, A., Garnett, J., Fosker, N., Hall, R., Garner, P., Kelly, D., Bird, C., Palmer, S., Gehring, I., Berger, A., Dooley, C.M., Ersan-Urun, Z., Eser, C., Geiger, H., Geisler, M., Karotki, L., Kirn, A., Konantz, J., Konantz, M., Oberlander, M., Rudolph-Geiger, S., Teucke, M., Osoegawa, K., Zhu, B., Rapp, A., Widaa, S., Langford, C., Yang, F., Carter, N.P., Harrow, J., Ning, Z., Herrero, J., Searle, S.M., Enright, A., Geisler, R., Plasterk, R.H., Lee, C., Westerfield, M., de Jong, P.J., Zon, L.I., Postlethwait, J.H., Nusslein-Volhard, C., Hubbard, T.J., Roest Crollius, H., Rogers, J. and Stemple, D.L. (2013): The zebrafish reference genome sequence and its relationship to the human genome. Nature, 496, 498-503.
38. Ishikawa, T., Takechi, K., Rahman, A., Ago, J., Matsumoto, N., Murakami, A. and Kamei, C. (2007): Influences of histamine H1 receptor antagonists on maximal electroshock seizure in infant rats. Biol. Pharm. Bull., 30, 477-480.
39. Ito, K., Sakakibara, T., Handa, A., Irie, Y., Tubozaki, M. and Matuda, A. (1981): Safety study of cisplatin (NK801) (Part 1). The Clinical Report, 15, 5-22. (in Japanese)
40. Jeong, J.Y., Kwon, H.B., Ahn, J.C., Kang, D., Kwon, S.H., Park, J.A. and Kim, K.W. (2008): Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res. Bull., 75, 619-628.
41. Kamei, C. (2001): Involvement of central histamine in amygdaloid kindled seizures in rats. Behav. Brain Res., 124, 243-250.
42. Kamei, C., Ohuchi, M., Sugimoto, Y. and Okuma, C. (2000): Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats. Brain Res., 887, 183-186.
43. Karim, A., Kook, C., Campion, J. and Doherty, M. (1977): Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats. Arch. Int. Pharmacodyn. Ther., 228, 222-236.
44. Khanna, N., Ray, A., Alkondon, M. and Sen, P. (1989): Effect of beta-adrenoceptor antagonists and some related drugs on maximal electroshock seizures in mice. Indian J. Exp. Biol., 27, 128-130.
45. Kim, S.Y. and Benowitz, N.L. (1990): Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Saf., 5, 393-420.
46. Kim, Y.J., Nam, R.H., Yoo, Y.M. and Lee, C.J. (2004): Identification and functional evidence of GABAergic neurons in parts of the brain of adult zebrafish (Danio rerio). Neurosci. Lett., 355, 29-32.
47. Krijzer, F., Snelder, M. and Bradford, D. (1984): Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology, 12, 249-254.
48. Kukko-Lukjanov, T.K., Lintunen, M., Jalava, N., Lauren, H.B., Lopez-Picon, F.R., Michelsen, K.A., Panula, P. and Holopainen, I.E. (2010): Involvement of histamine 1 receptor in seizure susceptibility and neuroprotection in immature mice. Epilepsy Res., 90, 8-15.
49. Kurt, M., Bilge, S.S., Kukula, O., Kesim, Y. and Celik, S. (2001): The role of nitrergic system in lidocaine-induced convulsion in the mouse. Jpn. J. Pharmacol., 85, 92-94.
50. Lee, V.C., Moscicki, J.C. and DiFazio, C.A. (1998): Propofol sedation produces dose-dependent suppression of lidocaine-induced seizures in rats. Anesth. Analg., 86, 652-657.
51. Leszczynska, K. and Kau, S.T. (1992): A sciatic nerve blockade method to differentiate drug-induced local anesthesia from neuromuscular blockade in mice. J. Pharmacol. Toxicol. Methods, 27, 85-93.
52. Lin, C.S., Cheng, C.J., Chou, C.H. and Lin, S.H. (2007): Piperacillin/ tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am. J. Med. Sci., 333, 181-184.
53. Lipsky, B.A. and Baker, C.A. (1999): Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis., 28, 352-364.
54. Locke, C.J., Williams, S.N., Schwarz, E.M., Caldwell, G.A. and Caldwell, K.A. (2006): Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans. Brain Res., 1120, 23-34.
55. Loscher, W. and Honack, D. (1992): The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol., 215, 199-208.
56. Love, J.N. and Handler, J.A. (1995): Toxic psychosis: an unusual presentation of propranolol intoxication. Am. J. Emerg. Med., 13, 536-537.
57. MacPhail, R.C., Brooks, J., Hunter, D.L., Padnos, B., Irons, T.D. and Padilla, S. (2009): Locomotion in larval zebrafish: Influence of time of day, lighting and ethanol. Neurotoxicology, 30, 52-58.
58. Malave, A., Holsapple, M.P. and Yim, G.K. (1983): Local anesthetic activity and disopyramide toxicity. Arch. Int. Pharmacodyn. Ther., 263, 254-263.
59. Manning, K.A. and Uhlrich, D.J. (2009): Acceleration of pentylenetetrazol seizure kindling associated with induction of sensitized visual responses evoked by strobe stimulation. Neuroscience, 163, 695-704.
60. March, P.A. (1998): Seizures: classification, etiologies, and pathophysiology. Clin. Tech. Small Anim. Pract., 13, 119-131.
61. Mareš, P. and Šlamberova, R. (2006): Opposite effects of a GABAB antagonist in two models of epileptic seizures in developing rats. Brain Res. Bull., 71, 160-166.
62. McHugh, T.P. and Perina, D.G. (1987): Propafenone ingestion. Ann. Emerg. Med., 16, 437-440.
63. Minns, A.B., Ghafouri, N. and Clark, R.F. (2010): Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr. Emerg. Care, 26, 380-381.
64. Mituzono, T., Ogawa, H., Isowa, K. and Ishimura, K. (1987): 13-Weeks-toxicity study of propafenone hydrochloride in dogs at oral administration. The Clinical Report, 21, 3931-3942. (in Japanese)
65. Miyata, I., Saegusa, H. and Sakurai, M. (2011): Seizure-modifying potential of histamine H1 antagonists: a clinical observation. Pediatr. Int., 53, 706-708.
66. Mueller, T., Vernier, P. and Wullimann, M.F. (2006): A phylotypic stage in vertebrate brain development: GABA cell patterns in zebrafish compared with mouse. J. Comp. Neurol., 494, 620-634.
67. Musser, J.M. and Anderson, K.L. (2001): Bioavailability and disposition of sodium and procaine penicillin G (benzylpenicillin) administered orally with milk to calves. J. Vet. Pharmacol. Ther., 24, 161-169.
68. Nakamura, T., Fukuda, H., Morita, Y., Soumi, K. and Kawamura, Y. (2003): Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system. J. Toxicol. Sci., 28, 35-45.
69. Nozaki, M., Takeda, N., Tanaka, K., Niwa, M., Inazumi, K., Kaida, T., Tsurumi, K. and Fujimura, H. (1991): Convulsion induced by concomitant use of new quinolone antibacterial and NSAID. Japanese Journal of Inflammation, 11, 343-348. (in Japanese)
70. Nuutinen, S. and Panula, P. (2010): Histamine in neurotransmission and brain diseases. Adv. Exp. Med. Biol., 709, 95-107.
71. Obradovic, T., Dobson, G.G., Shingaki, T., Kungu, T. and Hidalgo, I.J. (2007): Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm. Res., 24, 318-327.
72. Okazaki, K., Omori, M., Chihaya, Y., Nagata, R., Niizato, T. and Shimizu, I. (1994): Single dose and repeated dose toxicity studies of fluvoxamine maleate administered orally to rats for 13 weeks. The Clinical Report, 28, 4149-4168. (in Japanese)
73. Olson, K.R., Kearney, T.E., Dyer, J.E., Benowitz, N.L. and Blanc, P.D. (1993): Seizures associated with poisoning and drug overdose. Am. J. Emerg. Med., 11, 565-568.
74. Owens, R.C. Jr. and Ambrose, P.G. (2000): Clinical use of the fluoroquinolones. Med. Clin. North Am., 84, 1447-1469.
75. Pandey, R., Gupta, S., Tandon, S., Wolkenhauer, O., Vera, J. and Gupta, S.K. (2010): Baccoside a suppresses epileptic-like seizure/ convulsion in caenorhabditis elegans. Seizure, 19, 439-442.
76. Pardridge, W.M., Sakiyama, R. and Fierer, G. (1983): Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug. J. Clin. Invest., 71, 900-908.
77. Pardridge, W.M., Sakiyama, R. and Fierer, G. (1984): Blood-brain barrier transport and brain sequestration of propranolol and lidocaine. Am. J. Physiol., 247, R582-588.
78. Peitsaro, N., Sundvik, M., Anichtchik, O.V., Kaslin, J. and Panula, P. (2007): Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior. Biochem. Pharmacol., 73, 1205-1214.
79. Perucca, E. and Richens, A. (1979): Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. Br. J. Clin. Pharmacol., 8, 21-31.
80. Poschet, J.F., Hammond, S.M. and Fairclough, P.D. (1999): Characterisation of penicillin G uptake in human small intestinal brush border membrane vesicles. Gut, 44, 620-624.
81. Rambourg-Schepens, M.O., Grossenbacher, F., Buffet, M. and Lamiable, D. (1999): Recurrent convulsions and cardiac conduction disturbances after propafenone overdose. Vet. Hum. Toxicol., 41, 153-154.
82. Reith, D.M., Dawson, A.H., Epid, D., Whyte, I.M., Buckley, N.A. and Sayer, G.P. (1996): Relative toxicity of beta blockers in overdose. J. Toxicol. Clin. Toxicol., 34, 273-278.
83. Renier, C., Faraco, J.H., Bourgin, P., Motley, T., Bonaventure, P., Rosa, F. and Mignot, E. (2007): Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharmacogenet. Genomics, 17, 237-253.
84. Romero, J.A. and Kuczler, F.J.Jr. (1998): Isoniazid overdose: recognition and management. Am. Fam. Physician, 57, 749-752.
85. Sakai, K., Yoshikawa, N., Kinoshita, Y., Oshika, H. and Nakai, K. (1964): Correlation between convulsive action and metabolism of isoniazid. Jpn. J. Pharmacol., 14, 308-316.
86. Sameshima, H., Arimura, S., Nomura, M., Nagata, R. Niizato, T. and Shimizu, I. (1994): A repeated dose toxicity study of fluvoxamine maleate administered orally to beagles for 13 weeks. The Clinical Report, 28, 4169-4191. (in Japanese)
87. Sangalli, B.C. (1997): Role of the central histaminergic neuronal system in the CNS toxicity of the first generation H1-antagonists. Prog. Neurobiol., 52, 145-157.
88. Singh, G., Rees, J.H. and Sander, J.W. (2007): Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J. Neurol. Neurosurg. Psychiatry, 78, 342-349.
89. Sombati, S. and Delorenzo, R.J. (1995): Recurrent spontaneous seizure activity in hippocampal neuronal networks in culture. J. Neurophysiol., 73, 1706-1711.
90. Stankiewicz, J., Stankiewicz, M., Wiaderna-Stepień, D., Tomas, T. and Gralewicz, S. (1995): Effects of repeated systemic penicillin injections on nonconvulsive and convulsive epileptic seizures in the rat. Acta Neurobiol. Exp. (Wars), 55, 281-287.
91. Steeghs, N., de Jongh, F.E. and Sillevis Smitt, P.A. and van den Bent, M.J. (2003): Cisplatin-induced encephalopathy and seizures. Anticancer Drugs, 14, 443-446.
92. Tanaka, K., Watanabe, M., Iizuka, T. and Kohori, N. (1971): Toxicity study of disopyramide in mouse and rat. The Clinical Report, 5, 1628-1640. (in Japanese)
93. Traynelis, S.F. and Dingledine, R. (1988): Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice. J. Neurophysiol., 59, 259-276.
94. Treiman, D.M. (2001): GABAergic mechanisms in epilepsy. Epilepsia, 42, 8-12.
95. Tsutani, K. (2009): Various aspects of drug withdrawal. Jpn. J. Clin. Pharmacol. Ther., 40, 7-16. (in Japanese)
96. Tubozaki, M. Hagiwara T., Ito, K., Irie, Y. and Matuda, A. (1981a): Safety study of cisplatin (NK801) (Part 2). The Clinical Report, 15, 5687-5718. (in Japanese)
97. Tubozaki, M. Hagiwara T., Ito, K., Irie, Y. and Matuda, A. (1981b): Safety study of cisplatin (NK801) (Part 3). The Clinical Report, 15, 5719-5751. (in Japanese)
98. Villar, D., Knight, M.K., Holding, J., Barret, G.H. and Buck, W.B. (1995): Treatment of acute isoniazid overdose in dogs. Vet. Hum. Toxicol., 37, 473-477.
99. Wang, Y.A., Zhou, W.X., Li, J.X., Liu, Y.O., Yue, Y.J., Zheng, J.O., Liu, K.L. and Ruan J.X. (2005): Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: Neurochemical mechanisms. Life Sci., 78, 210-223.
100. Wenk, G.L., Danysz, W. and Mobley, S.L. (1995): MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol., 293, 267-270.
101. Wilde, M.I., Plosker, G.L. and Benfield, P. (1993): Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs, 46, 895-924.
102. Winter, M.J., Redfern, W.S., Hayfield, A.J., Owen, S.F., Valentin, J.P. and Hutchinson, T.H. (2008): Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs. J. Pharmacol. Toxicol. Methods, 57, 176-187.
103. Wong, K., Stewart, A., Gilder, T., Wu, N., Frank, K., Gaikwad, S., Suciu, C., DiLeo, J., Utterback, E., Chang, K., Grossman, L., Cachat, J. and Kalueff, A.V. (2010): Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish. Brain Res., 1348, 209-215.
104. Wu, F.L., Razzaghi, A. and Souney, P.F. (1993): Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia. Pharmacotherapy, 13, 72-78.
105. Wyngarden, J.B. and Seevers, M.H. (1951): The toxic effects of antihistaminic drugs. J. Am. Med. Assoc., 145, 277-282.
106. Yamada, K., Takizawa, F., Tamura, T. and Kanda T. (2012): The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats. Biol. Pharm. Bull., 35, 693-697.
107. Yawata, I., Tanaka, K., Nakagawa, Y., Watanabe, Y., Murashima, Y.L. and Nakano, K. (2004): Role of histaminergic neurons in development of epileptic seizures in EL mice. Brain Res. Mol. Brain Res., 132, 13-17.
108. Yokoyama, H. (2001): The role of central histaminergic neuron system as an anticonvulsive mechanism in developing brain. Brain Dev., 23, 542-547.
109. Zaccara, G., Muscas, G.C. and Messori, A. (1990): Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf., 5, 109-151.
110. Zolaly, M.A. (2012): Histamine H1 antagonists and clinical characteristics of febrile seizures. Int. J. Gen. Med., 5, 277-281.